NEW YORK (TheStreet) -- After imploding by more than half from the start of the year, buying J.C. Penney (JCP) may feel like stepping out on railroad tracks and stopping a freight train with your hand.
If you're too early, your account can get trampled faster than you can say "margin call," as many have found out. That's the reason why I've been critical of J.C. Penney, especially after they blindsided investors with a 38% share dilution that sent shares falling to multi-year lows. But as the facts change, so must our opinion.
The financial situation is the same, not much has materially improved, but instead of paying over $10 a share, we can now buy the retailer for under $8.50. In fact, I will show you how you can lower your risk to under $7 a share while leaving room of a possible 10% gain in about three months.
Top Dow Dividend Stocks To Buy For 2015: CyrusOne Inc (CONE)
CyrusOne Inc., incorporated on July 31, 2012, is a owner, operator and developer of enterprise-class, carrier-neutral data center properties. Enterprise-class, carrier-neutral data centers are purpose-built facilities with redundant power, cooling and telecommunications systems and that are not network-specific, enabling customer interconnectivity to a range of telecommunications carriers. The Company provides mission-critical data center facilities that protect operation of information technology (IT) infrastructure for approximately 500 customers. As of September 30, 2012, its customers included nine of the Fortune 20 and 108 of the Fortune 1000 or private or foreign enterprises of equivalent size. On July 31, 2012, the Company�� operating partnership, CyrusOne LP, was formed. On July 31, 2012, CyrusOne GP, the general partner of the Company�� operating partnership, was formed as a trust.
As of September 30, 2012, the Company�� property portfolio included 23 operating data centers in nine markets: Austin, Chicago, Cincinnati, Dallas, Houston, London, San Antonio, Singapore, and South Bend providing approximately 1,630,000 net rentable square feet (NRSF) and powered by approximately 125 megawatts of utility power. The Company owns nine of the buildings in which its data center facilities are located. It leases the remaining 14 buildings, which account for approximately 600,000 NRSF. The Company also has 379,000 NRSF under development at three data centers in three markets (Dallas, Houston and Phoenix) and 762,000 NRSF of additional powered shell space under roof and available for development. In addition, it has approximately 146 acres of land that are available for future data center facility development. Along with its primary product offering, leasing of colocation space, its customers are interested in its ancillary office and other space.
As of September 2012, the Company added 36,000 Colocation Space (CSF) at its Westover Hills Blvd (San Antonio) facility, 47,0! 00 CSF at its Frankford Road (Carrollton) facility and 15,000 CSF at its Westway Park Blvd (Houston West) facility. The Company�� portfolio of properties consists primarily of data centers geographically concentrated in cities in Ohio and Texas, which comprised 38% and 59%, respectively, of its annualized rent as of September 30, 2012.
Advisors' Opinion:- [By Paulo Santos]
As I started my due diligence on Cyrusone (CONE), I was excited. Here was a stock that had a good story - it rents out space in datacenters, has a dividend yield and trades at a low valuation while showing decent growth.
- [By Jim Royal]
To recap, Cincinnati Bell owns a 69% stake in CyrusOne (NASDAQ: CONE ) , which is worth over $1 billion now. It intends to monetize this asset some time following a lock-up period that ends in January. CyrusOne is growing quickly, and revenue could easily climb 20% this year. This is Cincinnati Bell's best asset and the rapid deleveraging ��I expect debt could be slashed by 70% in the next year or two -- should help boost free cash flow markedly.
Hot Railroad Companies To Watch In Right Now: Titan Pharmaceuticals Inc (TTNP)
Titan Pharmaceuticals, Inc., incorporated in February 1992, is a biopharmaceutical company developing therapeutics primarily for the treatment of central nervous system (CNS) disorders. The Company is focused primarily on clinical development of products that include Probuphine for the treatment of opioid addiction; Iloperidone: for the treatment of schizophrenia and related psychotic disorders, and Spheramine for the treatment of advanced Parkinson�� disease. Titan Pharmaceuticals is directly developing its product candidates and also utilizing corporate partnerships, including a collaboration with Bayer Schering Pharma AG, Germany (Bayer Schering) for the development of Spheramine to treat Parkinson�� disease, and Vanda Pharmaceuticals, Inc. (Vanda) for the development of iloperidone for the treatment of schizophrenia and related psychotic disorders.
Probuphine
Probuphine is the first product to utilize the Company�� ProNeura long-term drug delivery technology. Probuphine is designed to provide continuous, long-term therapeutic levels of the drug buprenorphine, an approved agent for the treatment of opioid addiction. In December 2007, the Company completed enrollment in a randomized, double-blind, placebo-controlled, multi-center Phase III clinical study of Probuphine in the treatment of opioid addiction. This 150 patient study, which is being conducted in the United States, will evaluate the safety and effectiveness of treatment with Probuphine versus placebo in reducing opioid addiction over 24 weeks of treatment. This study is part of a registration directed program intended to obtain marketing approval of Probuphine for the treatment of opioid addiction in Europe and the United States.
Iloperidone
Iloperidone was evaluated in a Phase III program comprising over 3,500 patients at more than 200 sites in 24 countries, administered and funded by Novartis Pharma AG (Novartis). In three completed efficacy studies conducted by Novartis, ilop! eridone statistically reduced the symptoms of schizophrenia compared to placebo. Iloperidone has also been investigated in three 12-month safety studies, which confirm safety and tolerability. A dose dependent increase in the Q-T Corrected (QTc) interval was observed and investigated further in a clinical study, and no clinically significant adverse events were observed. In September 2007, Vanda submitted a new drug application (NDA) with the United States Food and Drug Administration (FDA) for iloperidone. The NDA for iloperidone was officially accepted for review by the FDA in November 2007.
Spheramine
Spheramine is a cell-based therapeutic that utilizes the Company�� cell-coated microcarrier (CCM) technology, which enables the development of cell-based therapies for minimally invasive, site-specific delivery to the central nervous system of therapeutic factors precisely where they are needed. Spheramine consists of microcarriers coated with human retinal pigment epithelial cells that are intended to enhance brain levels of dopamine, a neurotransmitter deficient in certain brain regions in Parkinson�� disease, leading to movement disorders. Preclinical studies have demonstrated the preliminary efficacy and safety of Spheramine, including blinded studies in a primate model of Parkinson�� disease. In June 2007, enrollment was completed in a current multi-center, randomized, double-blind, placebo-controlled clinical trial of Spheramine in Parkinson�� disease. This Phase IIb clinical study enrolled 71 patients with advanced Parkinson�� disease (Hoehn and Yahr Stages III and IV) to further evaluate the efficacy, safety, and tolerability of Spheramine.
Bayer Schering, the Company�� corporate partner for worldwide development and commercialization of Spheramine, is funding the clinical development program for Spheramine. Under an agreement, Bayer Schering has received exclusive, worldwide development, manufacturing and commercialization rights, and, in ad! dition to! the clinical and manufacturing development funding and milestone payments, Bayer Schering will pay Titan Pharmaceuticals a royalty on future product sales.
Advisors' Opinion:- [By CRWE]
Today, TTNP surged (+2.76%) up +0.018 at $.689 with 152,996 shares in play thus far (ref. google finance Delayed: 2:02PM EDT October 1, 2013).
Titan Pharmaceuticals, Inc. previously reported that the U.S. Food and Drug Administration (FDA) has granted the request for a meeting to discuss Probuphine庐. The meeting is scheduled for November 19, 2013. The FDA has designated this as a Type C meeting and has requested the submission of briefing materials by October 7, 2013.
Hot Railroad Companies To Watch In Right Now: Watson Pharmaceuticals Inc.(WPI)
Watson Pharmaceuticals, Inc., a specialty pharmaceutical company, engages in the development, manufacture, marketing, sale, and distribution of generic and brand pharmaceutical products in the United States, western Europe, Canada, Australasia, Asia, South America, and South Africa. The company offers its products for therapeutic categories, such as central nervous system, cardiovascular, hormones and synthetic substitutes, anti-infective agents, and urology. It operates in three segments: Global Generics, Global Brands, and Distribution. The Global Generics segment develops, manufactures, and sells generic pharmaceutical products, as well as distributes generic versions of third parties? brand products. This segment offers various dosage forms, such as oral solids, transdermals, injectables, inhalation products, and transmucosals for indications, including pregnancy prevention, pain management, depression, hypertension, and smoking cessation. The Global Brands segment pr omotes and co-promotes Rapaflo, Gelnique, Trelstar, Androderm, Crinone, ella, INFeD, Generess, sodium ferric gluconate, AndroGel, and Femring branded products; and markets its products through sales professionals. It also sells various non-promoted products. The Distribution segment distributes generic and select brand pharmaceutical products, vaccines, injectables, and over-the-counter medicines to independent pharmacies, alternate care providers, pharmacy chains, and physicians? offices. The company sells its generic and brand pharmaceutical products primarily to drug wholesalers, retailers, and distributors, including national retail drug and food store chains, hospitals, clinics, mail order, government agencies, and managed healthcare providers, such as health maintenance organizations and other institutions. Watson Pharmaceuticals, Inc. was founded in 1983 and is headquartered in Parsippany, New Jersey.
Advisors' Opinion:- [By Louis Navellier]
Actavis Plc is one of the world’s largest generic drugmakers. For the past three decades, this company was known as Watson Pharmaceuticals (WPI), but the company rebranded itself as Actavis in 2013. With a portfolio of over 190 pharmaceutical product families, Actavis has its name on everything from antibiotics to contraceptives to smoking cessation treatments.
- [By Holly LaFon] n Pharmaceuticals stock has been on a decidedly upward trajectory in the last five years, increasing 108 percent. It became slightly cheaper in 2011, however. Dalio has been trading the stock for years but most recently he bought 314,360 shares at about $65 per share in the fourth quarter of 2011 after the stock had ventured off of its 52-week high of $73.35 it climbed to in the middle of the year.
Watson has a long-term record of profitability and growth, with an 11.9% 10-year revenue per share growth rate and 14.2% 10-year free cash flow per share growth rate.
Though the stock price declined in late 2011, the company in November reported double-digit net revenue and earnings growth. The company also announced that month an exclusive agreement with Pfizer Inc. (PFE) to launch a generic version of Lipitor, the world�� best-selling drug in the history of pharmaceuticals. It also received approval from the FDA to start producing a generic version of the birth control drug Yaz that month, a drug with sales of $173 million in the 12 months ending Sept. 30, 2011.
In February, Watson announced a full-year 2011 net revenue increase of 29 percent and EPS increase of 39 percent, due in large part to the successful launch of a total of 189 generic products globally for the year. Currently it is using its strong cash position to invest in growth markets, Canada and European operations.
In spite of the good news and increasing its full-year revenue forecast by $100 million to about $5.4 billion, the stock is up just 0.05 percent year to date.
Dalio�� next largest purchase was Berkshire Hathaway Inc. (BRK.B), and three new buys: BCE Inc. (BCE), The Goldman Sachs Group Inc. (GS), and Peabody Energy Corp. (BTU).
Dalio staking over 32 percent of his fund in emerging markets is tantamount to a forecast that emerging markets will outperform from the macro guru. His other top purchases have clear growth prospects. To see more of what Dalio
Hot Railroad Companies To Watch In Right Now: United-Guardian Inc.(UG)
United-Guardian, Inc. researches, develops, manufactures, and markets cosmetic ingredients, personal and health care products, pharmaceuticals, and specialty industrial products in the United States, Canada, China, France, and internationally. Its personal care products include LUBRAJEL, a line of water-based moisturizing and lubricating gel formulations; KLENSOFT, a surfactant for cosmetic formulations; UNITWIX, a cosmetic additive used as a thickener for oils and oil-based liquids; CONFETTI DERMAL DELIVERY FLAKES for use in various water-based products; ORCHID COMPLEX, a base for cosmetics; LUBRASLIDE and B-122 lubricants used in cosmetics; AQUATHIK, a powder used as a gelling agent for aqueous solutions or emulsions; and HYDRAJEL PL, a personal lubricant for the feminine personal care market. The company?s medical products comprise LUBRAJEL RR and RC water-based gels used as lubricants for catheters; LUBRAJEL MG to lubricate urinary catheters, prelubricated enema tips, and other medical devices; LUBRAJEL LC, a mouth moisturizer for oral use; and LUBRAJEL FLUID to lubricate water-soluble products. Its pharmaceuticals consists of RENACIDIN, a prescription drug to prevent and dissolve calcifications in urethral catheters and the urinary bladder; and CLORPACTIN WCS-90, an antimicrobial for use in urology and surgery to treat infections in the urinary bladder. United-Guardian?s industrial products include DESELEX Liquid, a sequestering and chelating agent; and POLYCOMPLEX M and Q complexing agents to produce clear solutions of water-insoluble materials. The company distributes its products to drug wholesalers, drug stores, hospitals, physicians, long-term care facilities, Veteran?s Administration, and other government agencies through marketing partners, distributors, advertising in medical and trade journals, mailings to physicians, and exhibitions. United-Guardian, Inc. was founded in 1942 and is based in Hauppauge, New York.
Advisors' Opinion:- [By Marc Bastow]
Cosmetics maker United-Guardian (UG) raised its semi-annual dividend 13% to 50 cents per share, payable on Dec. 20 to shareholders of record as of Dec. 6. This marks the 37th consecutive annual increase to the dividend.
UG Dividend Yield: 4.86% - [By Namitha Jagadeesh]
PSA Peugeot Citroen (UG) climbed 17 percent. Europe�� second- largest automaker reported first-quarter revenue fell 6.5 percent to 13 billion euros, beating the 12.7 billion-euro average analyst estimate in a Bloomberg survey, as delivery growth in China and Latin America limited the decline.
No comments:
Post a Comment